New PET tracer aims to reveal hidden immune activity in tumors and arteries
NCT ID NCT04758650
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the tracer's uptake matches disease activity or treatment response. The study was terminated early, so findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 68GaNOTA-Anti-MMR-VHH2 (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this imaging method could help doctors see specific immune cells in tumors and inflamed tissues, potentially guiding treatment decisions.
- What could go wrong
- The trial was terminated early with only 29 participants, so results are limited. It is an early-phase imaging study, not a treatment, and may not lead to routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS OF ARTERY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Uz Brussel
Brussels, Brussels Capital, 1090, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Could a stent double the chance of a good recovery after severe stroke?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare